Merck and Schering-Plough agreed Wednesday to pay $41.5 million to settle class-action lawsuits that accused them of withholding unfavorable results of a clinical trial of the cholesterol drugs Vytorin and Zetia.
Más...
En agosto 2008 publicamos notas sobre los estudios en curso con esta asociación. Denunciamos los Comunicados de Sociedades Médicas respaldando el producto.
Luego surgieron informaciones esperanzadoras. Ahora ya no lo son tanto y, al parecer, bastante concluyentes...
Esperamos ahora los comunicados de la Asociación Venezolana de Aterosclerosis y la Sociedad Venezolana de Medicina Interna...O será que ahora no se pronuncian como entonces?
The review notes that trials conducted with patient orientated clinical outcomes have so
far failed to prove a benefit. It is therefore recommended that in patients with cardiovascular disease or in those at risk of developing it, “every effort should be made to reduce LDL-cholesterol with a statin alone“. Additionally, use of the combination product (Inegy®) is discouraged based on the premium price for the single tablet. 
The finding of increased numbers of incident and fatal cancers in the simvastatin–ezetimibe group, as compared with the placebo group, was unexpected and requires further exploration in trials of simvastatin and ezetimibe.
Ver...
Entradas
No hay comentarios:
Publicar un comentario